Literature DB >> 10868629

High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response.

L Bühler1, M Awwad, M Basker, S Gojo, A Watts, S Treter, K Nash, G Oravec, Q Chang, A Thall, J D Down, M Sykes, D Andrews, R Sackstein, M E White-Scharf, D H Sachs, D K Cooper.   

Abstract

BACKGROUND: In pig-to-primate organ transplantation, hyperacute rejection can be prevented, but the organ is rejected within days by acute vascular rejection, in which induced high-affinity anti-Gal alpha1-3Gal (alphaGal) IgG and possibly antibodies directed against new porcine (non-alphaGal) antigenic determinants are considered to play a major role. We have explored the role of an anti-CD40L monoclonal antibody in modifying the humoral response to porcine hematopoietic cells in baboons pretreated with a nonmyeloablative regimen.
METHODS: Porcine peripheral blood mobilized progenitor cells obtained by leukapheresis from both major histocompatibility complex-inbred miniature swine (n=7) and human decay-accelerating factor pigs (n=3) were transplanted into baboons. Group 1 baboons (n=3) underwent whole body (300 cGy) and thymic (700 cGy) irradiation, T cell depletion with ATG, complement depletion with cobra venom factor, short courses of cyclosporine, mycophenolate mofetil, porcine hematopoietic growth factors, and anti-alphaGal antibody depletion by immunoadsorption before transplantation of high doses (2-4 x 10(10)/cells/kg) of peripheral blood mobilized progenitor cells. In group 2 (n=5), cyclosporine was replaced by eight doses of anti-CD40L monoclonal antibodies over 14 days. The group 3 baboons (n=2) received the group 1 regimen plus 2 doses of anti-CD40L monoclonal antibodies (on days 0 and 2).
RESULTS: In group 1, sensitization to alphaGal (with increases in IgM and IgG of 3- to 6-fold and 100-fold, respectively) and the development of antibodies to new non-alphaGal porcine antigens occurred within 20 days. In group 2, no sensitization to alphaGal or non-alphaGal determinants was seen, but alphaGal-reactive antibodies did return to their pre- peripheral blood mobilized progenitor cells transplant levels. In group 3, attenuated sensitization to alphaGal antigens was seen after cessation of cyclosporine and mycophenolate mofetil therapy at 30 days (IgM 4-fold, IgG 8-30-fold), but no antibodies developed against new porcine determinants. In no baboon did anti-CD40L monoclonal antibodies prevent sensitization to its own murine antigens.
CONCLUSIONS: We believe these studies are the first to consistently demonstrate prevention of a secondary humoral response after cell or organ transplantation in a pig-to-primate model. The development of sensitization to the murine elements of the anti-CD40L monoclonal antibodies suggests that nonresponsiveness to cell membrane-bound antigen (e.g., alphaGal) is a specific phenomenon and not a general manifestation of immunological unresponsiveness. T cell costimulatory blockade may facilitate induction of mixed hematopoietic chimerism and, consequently, of tolerance to pig organs and tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10868629     DOI: 10.1097/00007890-200006150-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  39 in total

1.  Occurrence of specific humoral non-responsiveness to swine antigens following administration of GalT-KO bone marrow to baboons.

Authors:  Adam Griesemer; Fan Liang; Atsushi Hirakata; Erica Hirsh; Diana Lo; Masayoshi Okumi; Megan Sykes; Kazuhiko Yamada; Christene A Huang; David H Sachs
Journal:  Xenotransplantation       Date:  2010 Jul-Aug       Impact factor: 3.907

2.  Pig-to-baboon heterotopic heart transplantation--exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens.

Authors:  Hayato Iwase; Burcin Ekser; Vikas Satyananda; Jay Bhama; Hidetaka Hara; Mohamed Ezzelarab; Edwin Klein; Robert Wagner; Cassandra Long; Jnanesh Thacker; Jiang Li; Hao Zhou; Maolin Jiang; Santosh Nagaraju; Huidong Zhou; Massimiliano Veroux; Pietro Bajona; Martin Wijkstrom; Yi Wang; Carol Phelps; Nikolai Klymiuk; Eckhard Wolf; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2015-04-03       Impact factor: 3.907

Review 3.  A review of pig liver xenotransplantation: Current problems and recent progress.

Authors:  Xuan Zhang; Xiao Li; Zhaoxu Yang; Kaishan Tao; Quancheng Wang; Bin Dai; Shibin Qu; Wei Peng; Hong Zhang; David K C Cooper; Kefeng Dou
Journal:  Xenotransplantation       Date:  2019-02-15       Impact factor: 3.907

Review 4.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

Review 5.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

6.  B cell phenotypes in baboons with pig artery patch grafts receiving conventional immunosuppressive therapy.

Authors:  Takayuki Yamamoto; Qi Li; Hidetaka Hara; Liaoran Wang; Hongmin Zhou; Juan Li; Devin E Eckhoff; A Joseph Tector; Edwin C Klein; Ray Lovingood; Mohamed Ezzelarab; David Ayares; Yi Wang; David K C Cooper; Hayato Iwase
Journal:  Transpl Immunol       Date:  2018-08-06       Impact factor: 1.708

7.  Costimulation blockade in pig artery patch xenotransplantation - a simple model to monitor the adaptive immune response in nonhuman primates.

Authors:  Mohamed B Ezzelarab; Burcin Ekser; Gabriel Echeverri; Hidetaka Hara; Corin Ezzelarab; Cassandra Long; Pietro Bajona; Bertha Garcia; Noriko Murase; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2012 Jul-Aug       Impact factor: 3.907

Review 8.  Immunobiological barriers to xenotransplantation.

Authors:  David K C Cooper; Burcin Ekser; A Joseph Tector
Journal:  Int J Surg       Date:  2015-07-06       Impact factor: 6.071

9.  Frankenswine, or bringing home the bacon: How close are we to clinical trials in xenotransplantation?

Authors:  David Kc Cooper
Journal:  Organogenesis       Date:  2008-01       Impact factor: 2.500

10.  Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies.

Authors:  G L Palmisano; P L Tazzari; E Cozzi; A Bolognesi; L Polito; M Seveso; E Ancona; F Ricci; R Conte; F Stirpe; G B Ferrara; M P Pistillo
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.